March 2026 Prescription Drug Affordability Board Meeting

• Date and time: March 23rd, 2026 2:00 pm

Public Comment

The Board has set aside an opportunity for public comment during the meeting. Public comments must concern an agenda item and are limited to one minute and thirty seconds per comment. If you are interested in registering to make a public comment, please email [email protected]​ no later than the close of business on Wednesday, March 18, 2026, and provide:

1. Your name
2. Your address
3. The agenda item your comment will address. PDAB staff will reach out to you directly to confirm your reservation or provide additional detail.

Written Comment

The public may also submit written comments on the Board's pending decisions, or general comments regarding the Board's work, to [email protected]​​​. Please submit any written comments, concerning this agenda no later than the close of business on Wednesday, March 18, 2026. Please utilize the subject line “March 2026 Board Comments.”

Agenda and Meeting Materials

• A​gen​​da (Revised 3/18/2026)​ - PDF - 127.91 KB
• Meeting Recording
• Minutes - PDF - 109.93 KB
• 340B Study Report Update​ - PDF - 155.09 KB
• Updates to Cost Review Study Process and Policy Review Process​ - PDF - 255.28 KB
• Farxiga and Jardiance Cost Review Study Report Presentation - PDF - 349.14 KB
• Draft COMAR 14.01.06- Implementation and Monitoring of Upper Payment Limits - PDF - 103.07 KB
• Draft COMAR 14.01.07- Upper Payment Limit​​ - PDF - 161.92 KB
• ​Non-UPL Policy- WAC Penalty​ - PDF - 142.77 KB
• Non-UPL​ Policy- PBM Reimbursement- Delinking or Flat Fee​ - PDF - 115.24 KB
• Non- UPL Policy- Navigator Program​ - PDF - 126.62 KB

• Written Comment Packet - PDF - 1.34 MB

   

• Draft Farxiga Cost Review Study Report - PDF - 5.84 MB​
  • Appendix A Excel Exhibits:
    • Exhibit 3​ ​Farxiga Therapeutic Alternative Pricing REDACTED - XLSX - 315.17 KB
    • Exhibit 4 Farxiga Therapeutic Alternative Medical Claims Data Base (MCDB) Statistics​​ - XLSX - 150.25 KB
    • Exhibit 5
      • Exhibit 5A Farxiga Summary of Cost Effectiveness Analyses - XLSX - 27.66 KB 

      • Exhibit 5B Farxiga Summary of Comparative Effectiveness Research  - XLSX - 64.44 KB

         

• Draft Jardiance Cost Review Study Report - PDF - 5.3 MB
  • Appendix A Excel Exhibits:​
    • Exhibit 3​ ​Jardiance Therapeutic Alternative Pricing REDACTED - XLSX - 315.15 KB
    • Exhibit 4 Jardiance Therapeutic Alternative Medical Claims Data Base (MCDB) Statistics​​ - XLSX - 150.29 KB
    • Exhibit 5
      • Exhibit 5A Jardiance Summary of Co​st Effectiveness Analyses - XLSX - 117.71 KB
      • Exhibit 5B Jardiance Summary of Comparative Effectiveness Research - XLSX - 60.49 KB

Comments Received from the following:

• Community Access National Network
• EACH/PIC coalition
• Opinion Works